Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Inventiva S.A. - American Depository Shares (NQ:IVA)

4.495 -0.775 (-14.71%)
Streaming Delayed Price Updated: 1:15 PM EDT, Oct 29, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Inventiva S.A. - American Depository Shares

< Previous 1 2 3 4 5 Next >
12 Health Care Stocks Moving In Friday's Intraday Session
 
Via Benzinga
12 Health Care Stocks Moving In Wednesday's After-Market Session
 
Via Benzinga
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
 
Via Benzinga
Earnings Scheduled For March 26, 2025
 
Via Benzinga
12 Health Care Stocks Moving In Thursday's Pre-Market Session
 
Via Benzinga
12 Health Care Stocks Moving In Thursday's Pre-Market Session
 
Via Benzinga
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
 
Via Benzinga
12 Health Care Stocks Moving In Monday's Intraday Session
 
Via Benzinga
Why Is Fatty-Liver Drug Developer Inventiva Stock Trading Higher On Monday?
Inventiva secures €94.1M in financing, potentially reaching €348M, to fund the Phase 3 NATiV3 trial for lanifibranor in NASH. Leadership changes include new chairman and director appointments. 
Via Benzinga
12 Health Care Stocks Moving In Monday's Pre-Market Session
 
Via Benzinga
Why Longboard Pharmaceuticals Shares Are Trading Higher By Around 47%; Here Are 20 Stocks Moving Premarket
 
Via Benzinga
12 Health Care Stocks Moving In Thursday's Intraday Session
 
Via Benzinga
Gold Falls Over 1%; HilleVax Shares Plunge
 
Via Benzinga
Why Arhaus Shares Are Trading Lower By Around 8%? Here Are Other Stocks Moving In Monday's Mid-Day Session
 
Via Benzinga
Dow Turns Lower; Myomo Shares Jump
 
Via Benzinga
Topics Stocks
Why Paramount Global Shares Are Trading Higher By Around 8%; Here Are 20 Stocks Moving Premarket
 
Via Benzinga
Why Is Inventiva's Stock Trading Higher on Monday?
Inventiva's Lanifibranor improves cardiometabolic health in MASH/NASH patients. It lowers fasting glucose, reduces cardiovascular risk, and increases adiponectin levels. Weight gain correlates with... 
Via Benzinga
Madrigal Pharmaceuticals Wins Approval for the First Drug Targeting the Multibillion-Dollar NASH Market. Is the Stock a Screaming Buy?
Madrigal's Rezdiffra will have the NASH market all to itself -- at least for a while. 
Via The Motley Fool
12 Health Care Stocks Moving In Monday's Intraday Session
 
Via Benzinga
12 Health Care Stocks Moving In Monday's Pre-Market Session
 
Via Benzinga
Why DoorDash Shares Are Trading Lower By Around 12%? Here Are Other Stocks Moving In Friday's Mid-Day Session
Shares of DoorDash, Inc. (NASDAQ: DASH) fell sharply in today’s session as the company reported mixed financial results for its fourth quarter. 
Via Benzinga
12 Health Care Stocks Moving In Friday's Intraday Session
 
Via Benzinga
Why Is Liver Disease-Focused Inventiva Stock Trading Lower Today?
Inventiva announces a voluntary pause in NATiV3 Phase 3 trial of lanifibranor for NASH due to a treatment-related SUSAR. Screening and randomization halted temporarily. 
Via Benzinga
Why The Trade Desk Shares Are Trading Higher By Around 19%; Here Are 20 Stocks Moving Premarket
Shares of The Trade Desk, Inc. (NASDAQ: TTD) shares rose sharply in today’s pre-market trading after the company reported mixed fourth-quarter financial results< 
Via Benzinga
12 Health Care Stocks Moving In Friday's Pre-Market Session
 
Via Benzinga
Yelp Reports Q4 Results, Joins Roku, Dropbox And Other Big Stocks Moving Lower In Friday's Pre-Market Session
U.S. stock futures were mixed this morning, with the Nasdaq futures trading higher by around 100 points on Friday. 
Via Benzinga
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
 
Via Benzinga
Earnings Scheduled For September 28, 2023
Companies Reporting Before The Bell • CarMax (NYSE:KMX) is projected to report quarterly earnings at $0.78 per share on revenue of $7.03 billion. 
Via Benzinga
Investors Eye CymaBay's AFFIRM Study As Regulatory Uncertainties Ease
Thursday, CymaBay Therapeutics Inc (NASDAQ: CBAY) initiated the AFFIRM Phase 3b/4 confirmatory study to evaluate the effect of seladelpar on clinical outcomes in patients with compensated cirrhosis due... 
Via Benzinga
12 Health Care Stocks Moving In Wednesday's After-Market Session
 
Via Benzinga
< Previous 1 2 3 4 5 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.